A PROSPECTIVE OBSERVATIONAL STUDY ON DISTRIBUTION PATTERN OF ADVERSE EFFECTS OF BRONCHODILATORS AMONG BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL IN A RURAL AREA OF KANCHEEPURAM DISTRICT

KEERTHANA K; LAVAKUMAR SOMU; VISHWAMBHAR

doi:10.22159/ajpcr.2021.v14i2.40195

Authors

KEERTHANA K Department of Pharmacology, Shri Sathya Sai Medical College and Research Institute, SBV Deemed to be University, Pondicherry, India.
LAVAKUMAR SOMU Department of Pharmacology, Shri Sathya Sai Medical College and Research Institute, SBV Deemed to be University, Pondicherry, India.
VISHWAMBHAR Department of Respiratory Medicine, Shri Sathya Sai Medical College and Research Institute, SBV Deemed to be University, Pondicherry, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i2.40195

Keywords:

Adverse effects, Bronchodilators, Shri Sathya Sai Medical College

Abstract

Objectives: The objectives of the study were (i) to study the distribution pattern of adverse effects of bronchodilators at initiation or during the course of therapy, (ii) to make a causality assessment of adverse effect identified using the WHO adverse drug reaction (ADR) probability scale, and (iii) to identify next drug tolerated better by him/her.

Materials and Methods: This is an observational study that lasted for duration of 2 months.

Inclusion Criteria: All patients reporting ADR after initiation of bronchodilator or during the course of bronchodilator therapy for bronchial asthma/ chronic obstructive pulmonary disease within the study period were included in the study. The suspected adverse effect was noted and documented. Causality assessment based on the WHO scale was employed.

Results: During the study period, ten patients reported to have ADR for bronchodilators were identified and the WHO Causality Scale for ADR was applied and the better drug tolerated by the patient was noted.

Conclusion: Inhalational forms of longer acting beta-2 agonists were better compliable to the patients with no observable adverse effects.

Downloads

Download data is not yet available.

Author Biography

KEERTHANA K, Department of Pharmacology, Shri Sathya Sai Medical College and Research Institute, SBV Deemed to be University, Pondicherry, India.

PHARMACOLOGY

ASSISTANT PROFESSOR

References

International consensus report on diagnosis and treatment of asthma. National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication no. 92-3091, March 1992. Eur Respir J 1992;5:601-41.

Available from: https//www.researchgate.net publications.

Morley J. Beta agonists and asthma mortality: Déjà vu. Clin Exp Allergy 1992;22:724-5.

Gonnelli S, Caffarelli C, Maggi S, Guglielmi G, Siviero P, Rossi S, et al. Effect of inhaled glucocorticoids and β2 agonists on vertebral fracture risk in COPD patients: The EOLO study. Calcif Tissue Int 2010;87:137-43.

Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001;87:379-85.

Rohatagi S, Luo Y, Shen L, Guo Z, Schemm C, Huang Y, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005;12:201-9.

Voss HP, Donnell D, Bast A. Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol 1992;227:403-9.

Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005;14:775-83.